Global Acyclovir Intermediate Market Growth 2025-2031

Publication ID:

LPI07254608

Publication Date:

July 24, 2025

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Acyclovir Intermediate market size is predicted to grow from US$ 42.3 million in 2025 to US$ 61.3 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.
An acyclovir intermediate is a chemical compound used in the synthesis of acyclovir, an antiviral drug primarily used to treat herpes simplex and varicella-zoster infections. These intermediates serve as key precursors in the multi-step production process, ensuring the efficient and high-purity synthesis of the final active pharmaceutical ingredient (API).
United States market for Acyclovir Intermediate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Acyclovir Intermediate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Acyclovir Intermediate is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Acyclovir Intermediate players cover Fuxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals Co., Ltd., Shanghai Pharmaceuticals Kangli, Zhejiang Chetou Pharmaceuticals, Tongliao Desheng Bio-tech, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淎cyclovir Intermediate Industry Forecast鈥� looks at past sales and reviews total world Acyclovir Intermediate sales in 2024, providing a comprehensive analysis by region and market sector of projected Acyclovir Intermediate sales for 2025 through 2031. With Acyclovir Intermediate sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acyclovir Intermediate industry.
This Insight Report provides a comprehensive analysis of the global Acyclovir Intermediate landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Acyclovir Intermediate portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Acyclovir Intermediate market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acyclovir Intermediate and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acyclovir Intermediate.
This report presents a comprehensive overview, market shares, and growth opportunities of Acyclovir Intermediate market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Diacetylguanine
2,6-Dichloropurine
2-Amino-6-chloropurine
Other
Segmentation by Application:
Pharmaceuticals
Scientific Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Fuxiang Pharmaceuticals
Hubei Yitai Pharmaceuticals Co., Ltd.
Shanghai Pharmaceuticals Kangli
Zhejiang Chetou Pharmaceuticals
Tongliao Desheng Bio-tech
Hongyuan Pharmaceuticals
Xinxiang Pharmaceuticals
Zhejiang Oma Pharmaceuticals
Aotong Pharmaceuticals
Manus Aktteva Biopharma
AFINE CHEMICALS
AuroMedics
Hari Pharma
Fresenius Kabi
SteriMax
Key Questions Addressed in this Report
What is the 10-year outlook for the global Acyclovir Intermediate market?
What factors are driving Acyclovir Intermediate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Acyclovir Intermediate market opportunities vary by end market size?
How does Acyclovir Intermediate break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Acyclovir Intermediate Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Acyclovir Intermediate by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Acyclovir Intermediate by Country/Region, 2020, 2024 & 2031
2.2 Acyclovir Intermediate Segment by Type
2.2.1 Diacetylguanine
2.2.2 2,6-Dichloropurine
2.2.3 2-Amino-6-chloropurine
2.2.4 Other
2.3 Acyclovir Intermediate Sales by Type
2.3.1 Global Acyclovir Intermediate Sales Market Share by Type (2020-2025)
2.3.2 Global Acyclovir Intermediate Revenue and Market Share by Type (2020-2025)
2.3.3 Global Acyclovir Intermediate Sale Price by Type (2020-2025)
2.4 Acyclovir Intermediate Segment by Application
2.4.1 Pharmaceuticals
2.4.2 Scientific Research
2.5 Acyclovir Intermediate Sales by Application
2.5.1 Global Acyclovir Intermediate Sale Market Share by Application (2020-2025)
2.5.2 Global Acyclovir Intermediate Revenue and Market Share by Application (2020-2025)
2.5.3 Global Acyclovir Intermediate Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Acyclovir Intermediate Breakdown Data by Company
3.1.1 Global Acyclovir Intermediate Annual Sales by Company (2020-2025)
3.1.2 Global Acyclovir Intermediate Sales Market Share by Company (2020-2025)
3.2 Global Acyclovir Intermediate Annual Revenue by Company (2020-2025)
3.2.1 Global Acyclovir Intermediate Revenue by Company (2020-2025)
3.2.2 Global Acyclovir Intermediate Revenue Market Share by Company (2020-2025)
3.3 Global Acyclovir Intermediate Sale Price by Company
3.4 Key Manufacturers Acyclovir Intermediate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Acyclovir Intermediate Product Location Distribution
3.4.2 Players Acyclovir Intermediate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Acyclovir Intermediate by Geographic Region
4.1 World Historic Acyclovir Intermediate Market Size by Geographic Region (2020-2025)
4.1.1 Global Acyclovir Intermediate Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Acyclovir Intermediate Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Acyclovir Intermediate Market Size by Country/Region (2020-2025)
4.2.1 Global Acyclovir Intermediate Annual Sales by Country/Region (2020-2025)
4.2.2 Global Acyclovir Intermediate Annual Revenue by Country/Region (2020-2025)
4.3 Americas Acyclovir Intermediate Sales Growth
4.4 APAC Acyclovir Intermediate Sales Growth
4.5 Europe Acyclovir Intermediate Sales Growth
4.6 Middle East & Africa Acyclovir Intermediate Sales Growth
5 Americas
5.1 Americas Acyclovir Intermediate Sales by Country
5.1.1 Americas Acyclovir Intermediate Sales by Country (2020-2025)
5.1.2 Americas Acyclovir Intermediate Revenue by Country (2020-2025)
5.2 Americas Acyclovir Intermediate Sales by Type (2020-2025)
5.3 Americas Acyclovir Intermediate Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Acyclovir Intermediate Sales by Region
6.1.1 APAC Acyclovir Intermediate Sales by Region (2020-2025)
6.1.2 APAC Acyclovir Intermediate Revenue by Region (2020-2025)
6.2 APAC Acyclovir Intermediate Sales by Type (2020-2025)
6.3 APAC Acyclovir Intermediate Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Acyclovir Intermediate by Country
7.1.1 Europe Acyclovir Intermediate Sales by Country (2020-2025)
7.1.2 Europe Acyclovir Intermediate Revenue by Country (2020-2025)
7.2 Europe Acyclovir Intermediate Sales by Type (2020-2025)
7.3 Europe Acyclovir Intermediate Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Acyclovir Intermediate by Country
8.1.1 Middle East & Africa Acyclovir Intermediate Sales by Country (2020-2025)
8.1.2 Middle East & Africa Acyclovir Intermediate Revenue by Country (2020-2025)
8.2 Middle East & Africa Acyclovir Intermediate Sales by Type (2020-2025)
8.3 Middle East & Africa Acyclovir Intermediate Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Acyclovir Intermediate
10.3 Manufacturing Process Analysis of Acyclovir Intermediate
10.4 Industry Chain Structure of Acyclovir Intermediate
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Acyclovir Intermediate Distributors
11.3 Acyclovir Intermediate Customer
12 World Forecast Review for Acyclovir Intermediate by Geographic Region
12.1 Global Acyclovir Intermediate Market Size Forecast by Region
12.1.1 Global Acyclovir Intermediate Forecast by Region (2026-2031)
12.1.2 Global Acyclovir Intermediate Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Acyclovir Intermediate Forecast by Type (2026-2031)
12.7 Global Acyclovir Intermediate Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Fuxiang Pharmaceuticals
13.1.1 Fuxiang Pharmaceuticals Company Information
13.1.2 Fuxiang Pharmaceuticals Acyclovir Intermediate Product Portfolios and Specifications
13.1.3 Fuxiang Pharmaceuticals Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Fuxiang Pharmaceuticals Main Business Overview
13.1.5 Fuxiang Pharmaceuticals Latest Developments
13.2 Hubei Yitai Pharmaceuticals Co., Ltd.
13.2.1 Hubei Yitai Pharmaceuticals Co., Ltd. Company Information
13.2.2 Hubei Yitai Pharmaceuticals Co., Ltd. Acyclovir Intermediate Product Portfolios and Specifications
13.2.3 Hubei Yitai Pharmaceuticals Co., Ltd. Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Hubei Yitai Pharmaceuticals Co., Ltd. Main Business Overview
13.2.5 Hubei Yitai Pharmaceuticals Co., Ltd. Latest Developments
13.3 Shanghai Pharmaceuticals Kangli
13.3.1 Shanghai Pharmaceuticals Kangli Company Information
13.3.2 Shanghai Pharmaceuticals Kangli Acyclovir Intermediate Product Portfolios and Specifications
13.3.3 Shanghai Pharmaceuticals Kangli Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Shanghai Pharmaceuticals Kangli Main Business Overview
13.3.5 Shanghai Pharmaceuticals Kangli Latest Developments
13.4 Zhejiang Chetou Pharmaceuticals
13.4.1 Zhejiang Chetou Pharmaceuticals Company Information
13.4.2 Zhejiang Chetou Pharmaceuticals Acyclovir Intermediate Product Portfolios and Specifications
13.4.3 Zhejiang Chetou Pharmaceuticals Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Zhejiang Chetou Pharmaceuticals Main Business Overview
13.4.5 Zhejiang Chetou Pharmaceuticals Latest Developments
13.5 Tongliao Desheng Bio-tech
13.5.1 Tongliao Desheng Bio-tech Company Information
13.5.2 Tongliao Desheng Bio-tech Acyclovir Intermediate Product Portfolios and Specifications
13.5.3 Tongliao Desheng Bio-tech Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Tongliao Desheng Bio-tech Main Business Overview
13.5.5 Tongliao Desheng Bio-tech Latest Developments
13.6 Hongyuan Pharmaceuticals
13.6.1 Hongyuan Pharmaceuticals Company Information
13.6.2 Hongyuan Pharmaceuticals Acyclovir Intermediate Product Portfolios and Specifications
13.6.3 Hongyuan Pharmaceuticals Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Hongyuan Pharmaceuticals Main Business Overview
13.6.5 Hongyuan Pharmaceuticals Latest Developments
13.7 Xinxiang Pharmaceuticals
13.7.1 Xinxiang Pharmaceuticals Company Information
13.7.2 Xinxiang Pharmaceuticals Acyclovir Intermediate Product Portfolios and Specifications
13.7.3 Xinxiang Pharmaceuticals Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Xinxiang Pharmaceuticals Main Business Overview
13.7.5 Xinxiang Pharmaceuticals Latest Developments
13.8 Zhejiang Oma Pharmaceuticals
13.8.1 Zhejiang Oma Pharmaceuticals Company Information
13.8.2 Zhejiang Oma Pharmaceuticals Acyclovir Intermediate Product Portfolios and Specifications
13.8.3 Zhejiang Oma Pharmaceuticals Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Zhejiang Oma Pharmaceuticals Main Business Overview
13.8.5 Zhejiang Oma Pharmaceuticals Latest Developments
13.9 Aotong Pharmaceuticals
13.9.1 Aotong Pharmaceuticals Company Information
13.9.2 Aotong Pharmaceuticals Acyclovir Intermediate Product Portfolios and Specifications
13.9.3 Aotong Pharmaceuticals Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Aotong Pharmaceuticals Main Business Overview
13.9.5 Aotong Pharmaceuticals Latest Developments
13.10 Manus Aktteva Biopharma
13.10.1 Manus Aktteva Biopharma Company Information
13.10.2 Manus Aktteva Biopharma Acyclovir Intermediate Product Portfolios and Specifications
13.10.3 Manus Aktteva Biopharma Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Manus Aktteva Biopharma Main Business Overview
13.10.5 Manus Aktteva Biopharma Latest Developments
13.11 AFINE CHEMICALS
13.11.1 AFINE CHEMICALS Company Information
13.11.2 AFINE CHEMICALS Acyclovir Intermediate Product Portfolios and Specifications
13.11.3 AFINE CHEMICALS Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 AFINE CHEMICALS Main Business Overview
13.11.5 AFINE CHEMICALS Latest Developments
13.12 AuroMedics
13.12.1 AuroMedics Company Information
13.12.2 AuroMedics Acyclovir Intermediate Product Portfolios and Specifications
13.12.3 AuroMedics Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 AuroMedics Main Business Overview
13.12.5 AuroMedics Latest Developments
13.13 Hari Pharma
13.13.1 Hari Pharma Company Information
13.13.2 Hari Pharma Acyclovir Intermediate Product Portfolios and Specifications
13.13.3 Hari Pharma Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Hari Pharma Main Business Overview
13.13.5 Hari Pharma Latest Developments
13.14 Fresenius Kabi
13.14.1 Fresenius Kabi Company Information
13.14.2 Fresenius Kabi Acyclovir Intermediate Product Portfolios and Specifications
13.14.3 Fresenius Kabi Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Fresenius Kabi Main Business Overview
13.14.5 Fresenius Kabi Latest Developments
13.15 SteriMax
13.15.1 SteriMax Company Information
13.15.2 SteriMax Acyclovir Intermediate Product Portfolios and Specifications
13.15.3 SteriMax Acyclovir Intermediate Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 SteriMax Main Business Overview
13.15.5 SteriMax Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂